(Q30582623)

25 June 2017

1 reference

title

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis (English)

1 reference

25 June 2017

1 reference

Lumry WR

1

1 reference

25 June 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

The Journal of Allergy and Clinical Immunology

25 June 2017

published in

1 reference

25 June 2017

volume

104

1 reference

25 June 2017

issue

4 Pt 1

1 reference

25 June 2017

page(s)

S150-8

1 reference

Development of fluticasone propionate and comparison with other inhaled corticosteroids

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Immunologic effects of intranasal corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Cytokine inhibition by a novel steroid, mometasone furoate

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Clinical review of once-daily beclomethasone dipropionate for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

The effects of topical nasal steroids on rat respiratory mucosa in vivo, with special reference to benzalkonium chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2899%2970311-8

7 January 2021

10.1016/S0091-6749(99)70311-8

Identifiers

DOI

1 reference

25 June 2017

1 reference